We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets close in 3 hrs 8 mins

Proteostasis Therapeutics, Inc. (PTI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.81-0.04 (-1.40%)
As of 12:50PM EDT. Market open.
Full screen
Previous Close2.85
Open2.84
Bid2.79 x 900
Ask2.80 x 900
Day's Range2.78 - 2.84
52 Week Range1.41 - 8.61
Volume86,820
Avg. Volume821,968
Market Cap101.388M
Beta4.21
PE Ratio (TTM)N/A
EPS (TTM)-1.99
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.75
Trade prices are not sourced from all markets
  • PR Newswire21 days ago

    Proteostasis Added to the Russell 3000® Index

    BOSTON, June 25, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced that the Company's stock was added to the Russell 3000® Index when the Russell Investment Group reconstituted its family of U.S. indexes following market close on June 22, 2018. "Inclusion in the Russell 3000 Index increases liquidity and raises visibility for PTI among a broader group of investors at a time where we anticipate reaching multiple clinical milestones for our novel cystic fibrosis transmembrane conductance regulator (CFTR) modulators," said Meenu Chhabra, President and Chief Executive Officer of Proteostasis.

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Proteostasis Therapeutics and Ophthotech Corporation

    NEW YORK, NY / ACCESSWIRE / June 8, 2018 / While Proteostasis Therapeutics announced positive results from an ongoing 14-day dosing study of PTI-801, an analyst at RBC Capital Markets didn't seem impressed and downgraded the company this week as well as lowered his price target on shares. Ophthotech Corporation saw a different story yesterday, gaining over 10% after announcing that it has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania. The results had shown statistically significant improvement in sweat chloride, body mass index, and weight and blood glucose.

  • Proteostasis Therapeutics (PTI) Enters Oversold Territory
    Zackslast month

    Proteostasis Therapeutics (PTI) Enters Oversold Territory

    Proteostasis Therapeutics, Inc. (PTI) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

  • GlobeNewswirelast month

    Analysis: Positioning to Benefit within Proteostasis Therapeutics, Yum China, Pretium Resources, Lexington Realty Trust, AngloGold Ashanti, and New Gold — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, June 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Proteostasis ...

  • Benzingalast month

    More Data Needed On Proteostasis Therapeutics' Cystic Fibrosis Candidate, RBC Says In Downgrade

    After  Proteostasis Therapeutics Inc (NASDAQ: PTI )’s mixed Phase 2 results from a study of its PTI-801 cystic fibrosis transmembrane conductance regulator, RBC Capital Markets said more data is necessary ...

  • PR Newswirelast month

    Proteostasis Announces Positive Data from Ongoing Phase 1 Study of PTI-801 in Cystic Fibrosis Patients on Background Orkambi® Therapy

    Results Show Statistically Significant Improvement in Sweat Chloride, Body Mass Index, Weight and Blood Glucose Treatment Led to a Statistically Significant Improvement in Blood Glucose Levels and the ...

  • ACCESSWIRElast month

    Initiating Free Research Reports on Pulmatrix and Three Other Biotech Equities

    Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Proteostasis Therapeutics Inc. (NASDAQ: PTI), Prothena Corp. PLC (NASDAQ: PRTA), PTC Therapeutics Inc. (NASDAQ: PTCT), and Pulmatrix Inc. (NASDAQ: PULM).

  • PR Newswirelast month

    Proteostasis Announces Presentations at the 41st European Cystic Fibrosis Society Conference

    BOSTON , June 1, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to ...

  • PR Newswire2 months ago

    Proteostasis Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

    BOSTON, May 31, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Po-Shun Lee, M.D., the Company's Chief Medical Officer, will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 2:30 p.m. ET in New York City. A live audio webcast of the Jefferies 2018 Global Healthcare Conference presentation will be available on the Investor Events page in the Investors & Media section of the Company's website, www.proteostasis.com. A replay of the webcast will be available on the Company's website following the presentation.

  • PR Newswire2 months ago

    Proteostasis Announces Formation of Independent Steering Committee of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for PTI-428 in Cystic Fibrosis

    BRIGHTON, Mass., May 8, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today the formation of an independent Steering Committee to guide the Phase 3 global clinical development program for PTI-428. This Steering Committee of leading CF experts will advise on the design and implementation of the Phase 3 global clinical program for PTI-428, the Company's novel cystic fibrosis transmembrane conductance regulator (CFTR) amplifier.